METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES

Provided is a method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors, and said method using 1-fluoro-4-nitrobenzen as a starting material. According to the method of the present invention, (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors can be prepared in a high purity and a high yield. The present invention relates to a method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors.(S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide of Formula (I-A) serves as an inhibitor against blood coagulation factor Xa and can be used for treating and preventing thrombosis, myocardial infarction, arteriosclerosis, inflammatory, apoplexy, angina pectoris, recurrent stricture after angioplasty, and thromboembolism such as intermittent claudication.The method for preparing the above-mentioned compound having an inhibitory effect against factor Xa is disclosed in Korean Patent No. 898361 which is filed by the present inventors. However, said method has problems in that the total production yield is low and column chromatography must be employed in the purification process of each step, which makes it not suitable for mass production.Therefore, it is an object of the present invention to provide a novel and simple method for preparing a high purity (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives in a high total yield by using a crystallization or ...

Method for preparing 5-chloro-n-(methyl)thiophen-2-carboxamide derivative and intermediate used therein

Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin- 1 -yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)thiophene-2-carboxamide derivative, which is a inhibitor of blood coagulation factor Xa, in a high purity and yield; and a novel intermedicate used therein.

POPPET VALVE ASSEMBLY FOR CONTROLLING A PNEUMATIC ACTUATOR

A poppet valve assembly to control a pneumatic actuator may include a housing having a central bore. A first module may be disposed within the central bore, and the first module may have a first and second poppet valve. A second module may also be disposed within the central bore, and the second module may have a third and fourth poppet valve. A supply of pressurized fluid may be in fluid communication with a plurality of control valves such that pressurized fluid from the control valves opens and closes the poppet valves. The supply of pressurized fluid may also be in fluid communication with the first module and the second module such that the opening and closing of the poppet valves controls the position of the pneumatic actuator. 1. A poppet valve assembly comprising:a valve housing having a central bore;a first module disposed within the central bore, the first module comprising a first normally closed poppet valve and a second normally closed poppet valve, wherein each of the first and second normally closed poppet valves has an open position and a closed position;a central port formed in the first module, wherein the central port of the first module is adapted to be coupled to a first volume of a pneumatic cylinder;an exhaust port formed in the first module such that the central port is in fluid communication with the exhaust port when the first poppet valve is in the open position; anda supply port formed in the first module such that the central port is in fluid communication with the supply port when second poppet valve is in the open position,wherein the supply port is configured to be in fluid communication with a supply of pressurized fluid such that when the second poppet valve is in the open position, pressurized fluid is provided to the first volume of the pneumatic cylinder, andwherein the exhaust port is configured to vent pressurized fluid from the first volume of the pneumatic cylinder when the first poppet valve is in the open position.2. The ...

NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. 6. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 1 , an in vivo hydrolysable ester thereof claim 1 , an in vivo hydrolysable phosphate ester thereof claim 1 , an isomer thereof claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 1 , diluent claim 1 , adjuvant claim 1 , or any combination thereof claim 1 , as an effective ingredient.7. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 2 , an in vivo hydrolysable ester thereof claim 2 , an in vivo hydrolysable phosphate ester thereof claim 2 , an isomer thereof claim 2 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 2 , diluent claim 2 , adjuvant claim 2 , or any combination thereof claim 2 , as an effective ingredient.8. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 3 , an in vivo hydrolysable ester thereof claim 3 , an in vivo hydrolysable phosphate ester thereof claim 3 , an isomer thereof claim 3 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 3 , diluent claim 3 , adjuvant claim 3 , or any combination thereof claim 3 , as an effective ingredient.9. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 4 , an in vivo hydrolysable ester thereof claim 4 , an in vivo hydrolysable phosphate ester thereof claim 4 , an isomer thereof claim 4 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 4 , diluent claim 4 , adjuvant claim 4 , or any combination thereof claim 4 , as an effective ingredient.10. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 5 , an in vivo hydrolysable ester thereof claim 5 , an in vivo ...

PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates, as well as methods for making the conjugates and compositions. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent). 1. A protein-active agent conjugate comprising a protein having an amino acid motif that can be recognized by an isoprenoid transferase , wherein the active agent is covalently linked to the protein at the amino acid motif.2. The protein-active agent conjugate of claim 1 , wherein the protein comprises a modification selected from the group consisting essentially of:(i) a deletion in the carboxy terminus of the protein;(ii) an oligopeptide or polypeptide addition in the carboxy terminus of the protein; and(iii) a deletion in the carboxy terminus of the protein and an oligopeptide or polypeptide addition in the carboxy terminus of the protein;wherein the modification is attached to the amino acid motif.3. The protein-active agent conjugate of claim 1 , wherein the protein is an antibody or a fragment of an antigenic polypeptide.4. The protein-active agent conjugate of claim 3 , wherein the protein is a monoclonal antibody.5. The protein-active agent conjugate of claim 4 , wherein at least one light chain and/or at least one heavy chain of the monoclonal antibody comprises an amino acid region having the amino acid motif.6. The protein-active agent conjugate of claim 1 , wherein the isoprenoid transferase is FTase or GGTase.7. The protein-active agent conjugate of claim 1 , wherein the active agent is a drug claim 1 , a toxin claim 1 , an affinity ligand claim 1 , a detection probe claim 1 , or a combination thereof.8. The protein-active agent conjugate of claim 1 , wherein ...

VALVE SIGNATURE DIAGNOSIS AND LEAK TEST DEVICE

A valve signature diagnosis and leak testing device includes a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position. A blocker valve is fluidly connected to a control fluid outlet of the spool valve. An electrical module is operatively connected to the pilot valve, a supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or closed position. 1. A valve signature diagnosis and leak testing device for a control valve , the valve signature diagnosis and leak testing device comprising:a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position, the spool valve including a first control fluid inlet, a first control fluid outlet, and a second control fluid outlet, the first control fluid inlet being fluidly connected to a supply of control fluid and the first control fluid outlet being configured to be connected to a valve actuator;a blocker valve fluidly connected to the second control fluid outlet; andan electrical module operatively connected to the pilot valve, the supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or a closed position,wherein the open position of the spool valve fluidly connects the first control fluid inlet to the first control fluid outlet and the closed position of the spool valve fluidly connects the first control fluid outlet to the second control fluid outlet.2. The valve signature diagnosis and leak testing device of claim 1 , wherein the electrical module includes a main ...

METHOD FOR PREPARING (R)-3-(3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1,2,4-TRIAZIN-4(1H)-YL)PHENYL)-5-(SUBSTITUTED METHYL)OXAZOLIDIN-2-ONE DERIVATIVES

Provided are a method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives, which are oxazolidinone antibiotic compounds having a cyclic amidrazone group, represented by Chemical Formula 1, and intermediates thereof, and uses 3,4-difluoro-4-nitrobenzen as a starting material. According to the preparation method of the present invention, (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives, which are useful as oxazolidinone antibiotics, can be prepared in high purity and high yield in a simpler manner than conventional methods. The following disclosure relates to a method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives, which are oxazolidinone antibiotic compounds having a cyclic amidrazone group, represented by Chemical Formula 1, and intermediates thereof.In Chemical Formula, R is —OH or —NHC(═O)R; and Ris (C1-C6)alkyl or (C1-C6)alkoxy.Compound 1a ((R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one) having the following structure is an oxazolidinone antibiotic and may be used to treat infections by Gram-positive bacteria, and particularly, methicillin-resistant staphylococci (MRSA), vancomycin resistant enterococci (VRE), or the like.An antibiotic effect of the compound and a method for preparing the same have been disclosed in Korea Patent Application No. 10-2008-0093712 filed by the present inventor. However, since the overall reaction step of the preparing method is long, and column chromatography should be used in most of the purifying processes for each step, such that the method is not appropriate for mass production.An object of the present invention is to provide a method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-( ...

WIRELESS MONITORING AND CONTROL OF SAFETY STATIONS IN A PROCESS PLANT

A safety station for use in a process plant includes one or more leverless limit switches to detect activation of one or more parts of the safety station. The safety station further includes a wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, which is communicatively coupled to one or more control and/or monitoring devices. 1. A safety station for use in a process plant , the safety station comprising:one or more leverless limit switches to detect activation of one or more parts of the safety station; anda wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, wherein the base station device is communicatively coupled to one or more control and/or monitoring modules.2. The safety station of claim 1 , wherein the leverless limit switch is a GO® switch manufactured by the TopWorx corporation.3. The safety station of claim 1 , wherein the leverless limit switch remains latched until physically reset.4702. The safety station of claim 1 , wherein the wireless transmitter is the Rosemount dual input transmitter manufactured by the Emerson corporation.5. The safety station of claim 1 , wherein the wireless transmitter is an intrinsically safe wireless transmitter.6. The safety station of claim 1 , wherein the safety station is a safety shower and/or an eye wash station.7. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a remote touch screen panel.8. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a paperless recorder.9. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a workstation.10. A safety station monitoring and control system in a process plant claim 1 , the system comprising:one or more safety stations ...

SWITCH MODULE

A switch module used for position sensing may be operated in a number of modes for compatibility with a number of legacy position sensing products. A dry switch circuit can be configured to provide a direct output, emulating dry reed, high-side or low-side switched configurations. Alternatively, the dry switch circuit can be connected to an input of a NAMUR circuit to provide the known current output for that standard. In another configuration the dry switch can be selectively coupled to one of two NAMUR circuits allowing the switch module to provide a low-to-high current NAMUR output or a high-to-low current NAMUR output. 1. A switch module arranged and adapted to report a position of a moveable element external to the switch module , the switch module comprising:a first external connection, a second external connection, and a third external connection;a dry contact relay having a relay contact position responsive to a position of a component external to the switch module, the dry contact relay having a common connection, a normally open connection and a normally closed connection, where the normally open connection corresponds to a first position of the moveable element and the normally closed connection corresponding to a second position of the moveable;a NAMUR circuit having a first input connection pair and a first output connection pair;an electrical connection from the normally open connection of the dry relay to a first input of the first input connection pair of the NAMUR circuit;a selector operable to connect the common connection of the dry contact relay to i) a null contact of the selector or ii) a second input of the first input connection pair of the NAMUR circuit;a second electrical connection from the first output of the NAMUR circuit to one of the first external connection or the second external connection; anda third electrical connection between the second output of the NAMUR circuit to the third external connection;a first jumper that removeably ...

NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. 6. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 1 , an in vivo hydrolysable ester thereof claim 1 , an in vivo hydrolysable phosphate ester thereof claim 1 , an isomer thereof claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 1 , diluent claim 1 , adjuvant claim 1 , or any combination thereof claim 1 , as an effective ingredient.7. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 2 , an in vivo hydrolysable ester thereof claim 2 , an in vivo hydrolysable phosphate ester thereof claim 2 , an isomer thereof claim 2 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 2 , diluent claim 2 , adjuvant claim 2 , or any combination thereof claim 2 , as an effective ingredient.8. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 3 , an in vivo hydrolysable ester thereof claim 3 , an in vivo hydrolysable phosphate ester thereof claim 3 , an isomer thereof claim 3 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 3 , diluent claim 3 , adjuvant claim 3 , or any combination thereof claim 3 , as an effective ingredient.9. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 4 , an in vivo hydrolysable ester thereof claim 4 , an in vivo hydrolysable phosphate ester thereof claim 4 , an isomer thereof claim 4 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier claim 4 , diluent claim 4 , adjuvant claim 4 , or any combination thereof claim 4 , as an effective ingredient.10. A pharmaceutical composition comprising the novel cephalosporin derivative according to claim 5 , an in vivo hydrolysable ester thereof claim 5 , an in vivo ...

CONFIGURABLE PROCESS CONTROL DEVICE WITH ELECTRONIC DISPLAY ASSEMBLY

A configurable process control device, which includes a field device, such as a valve position controller, that can be configured by a user to emulate any one of a plurality of different types of process control devices, is provided with an electronic display assembly. The electronic display assembly is operatively connected with a control circuit that is arranged to respond to the specific configuration of the field device to cause the electronic display assembly to display information relevant to the specific type of control device the field device has been configured to emulate. The information may include safety certification information specific to each of the different types of process control devices that the field device can be configured to emulate. 1. A configurable process control device for use in a plurality of use environments , wherein at least one of a pre-defined plurality of certifications must be displayed in conjunction with the configurable process control device depending on which of the use environments the configurable process control device is to be used in , the configurable process control device comprising:a field device;a first control circuit operatively coupled to the field device, the first control circuit arranged to control the field device and arranged to be reconfigured by a user to allow the field device to selectively emulate any of a plurality of different process control device types;an electronic display assembly, the electronic display assembly arranged to selectively display different information; anda second control circuit, the second control circuit operatively coupled to the electronic display assembly and the first control circuit, the second control circuit having access to a plurality of different certification information sets, each certification information set corresponding to a different one of the plurality of different process control device types;wherein the second control circuit causes the electronic display ...

Compounds comprising self-immolative group

Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Antibody-active agent conjugates and methods of use

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

PIEZOELECTRIC LOUDSPEAKER

The present invention discloses a piezoelectric loudspeaker. The piezoelectric loudspeaker comprises a sound producing plate, a resonant sound-box, a surround and a reflective sound-box. The sound producing plate comprises a piezoelectric ceramic element. The resonant sound-box includes a first opening comprising a first carrying part. The sound producing plate is disposed on the first carrying part. A cavity resonator is formed between the sound producing plate and the resonant sound-box. The surround is disposed between the first carrying part and the sound producing plate. The reflective sound-box includes a second opening and a reflective output opening. The second opening comprises a second carrying part. The resonant sound-box is disposed on the second carrying part. A reflective cavity body is formed between the resonant sound-box and the reflective sound-box, and the reflective cavity body is connected the reflective output opening. 1. A piezoelectric loudspeaker , comprising:a sound producing plate including at least one piezoelectric ceramic element being able to vibrate the sound producing plate;a resonant sound-box including a first opening comprising a first carrying part, the sound producing plate being disposed on the first carrying part, and a cavity resonator being formed between the sound producing plate and the resonant sound-box;a surround disposed between the first carrying part and the sound producing plate; anda reflective sound-box including a second opening and a reflective output opening, a second carrying part formed on a partial of an inner edge of the seconding opening, the resonant sound-box being disposed on the second carrying part, a reflective cavity body being formed between the resonant sound-box and the reflective sound-box, the reflective output opening being disposed on a side of the reflective sound-box, and the reflective cavity body being communicating with the reflective output opening.2. The piezoelectric loudspeaker of ...

COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody. 1. An antibody-drug conjugate , comprising an anti-CD19 antibody; a linker; and an active agent , wherein:the linker comprises an O-substituted oxime; wherein:a) the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; andthe carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody; orb) the carbon atom of the oxime is substituted with a group that covalently links the oxime to the active agent; andthe oxygen atom of the oxime is substituted with a group that covalently links the oxime to the antibody.4. The antibody-drug conjugate of claim 2 , wherein the sugar or sugar acid is a monosaccharide.6. (canceled)7. The antibody-drug conjugate of claim 2 , wherein W is —C(O)— claim 2 , —C(O)NR′— claim 2 , —C(O)O— claim 2 , —S(O)NR′— claim 2 , —P(O)R″NR′— claim 2 , —S(O)NR′— claim 2 , or —PONR′— claim 2 , in each case where the C(O) claim 2 , S claim 2 , or P is directly bound to the phenyl ring claim 2 , and R′ and R″ are each independently hydrogen claim 2 , (C-C)alkyl claim 2 , (C-C)cycloalkyl claim 2 , (C-C)alkoxy claim 2 , (C-C)alkylthio claim 2 , mono- or di-(C-C)alkylamino claim 2 , (C-C)heteroaryl claim 2 , or (C-C)aryl.8. The antibody-drug conjugate of claim 2 , wherein W represents —C(O)NR′— claim 2 , where C(O) is bonded to the phenyl ring and NR′ is bonded to L.911-. (canceled)12. The antibody-drug conjugate of claim 1 , wherein the linker comprises an alkylene having 1 to 50 carbon atoms ...

COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody. 1. An antibody-drug conjugate , comprising an anti-EGFR antibody; a linker; and an active agent , wherein:the linker comprises an O-substituted oxime; wherein:a) the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; andthe carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody; orb) the carbon atom of the oxime is substituted with a group that covalently links the oxime to the active agent; andthe oxygen atom of the oxime is substituted with a group that covalently links the oxime to the antibody.4. The antibody-drug conjugate of claim 2 , wherein the sugar or sugar acid is a monosaccharide.6. (canceled)7. The antibody-drug conjugate of claim 2 , wherein W is —C(O)— claim 2 , —C(O)NR′— claim 2 , —C(O)O— claim 2 , —S(O)NR′— claim 2 , —P(O)R″NR′— claim 2 , —S(O)NR′— claim 2 , or —PONR′— claim 2 , in each case where the C(O) claim 2 , S claim 2 , or P is directly bound to the phenyl ring claim 2 , and R′ and R″ are each independently hydrogen claim 2 , (C-C)alkyl claim 2 , (C-C)cycloalkyl claim 2 , (C-C)alkoxy claim 2 , (C-C)alkylthio claim 2 , mono- or di-(C-C)alkylamino claim 2 , (C-C)heteroaryl claim 2 , or (C-C)aryl.8. The antibody-drug conjugate of claim 2 , wherein W represents —C(O)NR′— claim 2 , where C(O) is bonded to the phenyl ring and NR′ is bonded to L.911-. (canceled)12. The antibody-drug conjugate of claim 1 , wherein the linker comprises an alkylene ...

COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP

Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity. 3. The method of claim 1 , wherein W is —C(O)— claim 1 , —C(O)NR′— claim 1 , —C(O)O— claim 1 , —SONR′— claim 1 , —P(O)R″NR′— claim 1 , —SONR′— claim 1 , or —PONR′— claim 1 , and R′ and R″ are each independently hydrogen claim 1 , (C-C)alkyl claim 1 , (C-C)cycloalkyl claim 1 , (C-C)alkoxy claim 1 , (C-C)alkylthio claim 1 , mono-or di-(C-C)alkylamino claim 1 , (C-C)heteroaryl or (C-C)aryl.4. The method of claim 1 , wherein the linker L is alkylene having 1 to 50 carbon atoms and satisfies at least one of the following (i) to (iv):(i) the alkylene includes at least one unsaturated bond,(ii) the alkylene includes at least one heteroarylene,(iii) the carbon atom of the alkylene is substituted with one or more hetero atoms selected from nitrogen (N), oxygen (O), and sulfur (S), and(iv) the alkylene is further substituted with one or more alkyls having 1 to 20 carbon atoms.6. The method of claim 5 , wherein the linker L further includes a binding unit formed by 1 claim 5 ,3-dipolar cycloaddition reactions claim 5 , hetero-Diels Alder reactions claim 5 , nucleophilic substitution reactions claim 5 , non-aldol type carbonyl reactions claim 5 , additions to carbon-carbon multiple bonds claim 5 , oxidation reactions claim 5 , or click reactions.7. The method of claim 6 , wherein the binding unit is formed by a reaction between acetylene and azide claim 6 , or a reaction between an aldehyde or ketone group and hydrazine or hydroxylamine.9. The compound method of claim 6 , wherein the linker L further includes a connection unit represented by the following Chemical Formula F or G:{'br': None, 'sub': 2', 'r', '2', 'p', 'q, ...

Novel oxazolidinone derivative and medical composition containing same

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

Compositions and methods related to anti-cd19 antibody drug conjugates

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Methods of preparing antibody-active agent conjugates

The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agent. The invention also provides a composition comprising the antibody-active agent conjugate prepared by the methods. 1. A method for preparing an antibody-active agent conjugate , wherein the conjugate comprises an antibody , a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody , an isoprenoid unit operably linked to the cysteine residue , and an active agent ,the method comprising:(a) obtaining an antibody that is attached to an amino acid motif that can be recognized by an isoprenoid transferase;(b) obtaining a functionalized antibody by enzymatically prenylating, in the presence of the isoprenoid transferase, the obtained antibody with at least one isosubstrate of the isoprenoid transferase, wherein the isosubstrate contains at least one isoprenoid unit and a first functional group (FG1) attached thereto;(c) obtaining a functionalized active agent which is an active agent attached to a second functional group (FG2); and(d) reacting the FG1 of the functionalized antibody with the FG2 of the functionalized active agent to yield the antibody-active agent conjugate,wherein the conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agent.2. An antibody-active agent conjugate prepared by the method of .3. A composition comprising the antibody-active agent conjugate of .4. A method for preparing an antibody-active agent conjugate ...

Item Eligibility and/or Promotion Determination Application

In general, the present invention is directed to systems and methods of utilizing an application operating on a mobile device to determine any applicable offers or eligibility and rank such offers and eligibility for user selection. More specifically, a process may be conducted by a processor in communication with a mobile device and data stores including user data, retailer data, and/or product and service data, the process including comparing identification information associated with a product or service received from the mobile device with data in the data stores; determining the product or service and identifying any associated promotional offers or plan eligibility associated with the product or service, the user, and/or the retailer; ranking any promotional offers or plan eligibility based at least in part on size of promotion; transmitting to the mobile device an identifier of applicable promotional offers or plan eligibility. 1. A system , comprising:a processor; user data, including memberships, groups, plans, and/or entitlements associated with a user;', products and services offered by a retailer;', 'any promotional offers offered by the retailer;, 'retailer data, including, 'product and service data, including identification information of each product and service, and any promotional offers or plan eligibility associated with the product or service;, 'one or more data stores, the one or more data stores storing data comprisingwherein the processor is in selective communication with one or more retailers, manufacturers, membership plans, insurance providers, and/or entitlement providers to populate and update the one or more data stores;wherein the processor is in selective communication with a mobile device of the user; comparing first media data comprising identification information associated with a product or service received from the mobile device with product and service data stored in the one or more data stores;', 'based at least in part on the ...

QUICK DISCONNECT CONNECTOR ASSEMBLY

A quick-disconnect connector assembly includes a housing having a bore that extends up to but not through a first end of the housing. The connector assembly also includes a proximity switch disposed within the bore, and the proximity switch includes a switch body, a first contact member, and a second contact member. A portion of each of the first and second contact members extends from the switch body towards a second end of the housing. In a first switch position, a contact of a displaceable switching assembly is in contact with the first contact member, and in a second switch position, the contact is in contact with the second contact member. The connector assembly also includes an external connection assembly including a first pin that is electrically coupled to the first contact member and a second pin that is electrically coupled to the second contact member. 1. A quick-disconnect connector assembly comprising:a housing that extends along a longitudinal axis from a first end to a longitudinally-opposite second end, the housing including one or more interior surfaces that cooperate to define a bore that extends from the second end to a point adjacent to the first end such that the bore does not extend through the first end of the housing, wherein the bore includes a first bore portion; a switch body extending along a body longitudinal axis, the switch body having a first end disposed adjacent to the first end of the housing and a longitudinally-opposite second end; and', 'a first contact member and a second contact member, each of the first and second contact members having a first end and a longitudinally-opposite second end, the second end being disposed within the switch body and the first end being disposed external to the switch body, wherein a portion of each of the first and second contact members extends from the second end of the switch body towards the second end of the housing,', 'wherein in a first switch position, a contact of a displaceable ...

Adjustable orthotic foot brace and method for adjusting a foot brace

The orthotic foot brace for a person wearing a footwear generally has: a lower leg holder securable to a lower leg of the person for use, a lower leg strut connected to the lower leg holder and extending downwardly towards the footwear during use; a foot strut structurally connected to the lower leg strut and having at least one side portion, each side portion extending forwardly along a respective side of the footwear and extending outwardly along a respective side of the footwear; an instep strut provided in the form of an extension of the foot strut along a long axis of the footwear, the instep strut having a distal portion securable to the footwear, and at least a proximal portion being slidably connected to the foot strut in a manner to allow adjusting the extension distance of the distal portion to a selected position.

TRACEABLE METALLIC PRODUCTS AND METALLIC SUPPORT FOR NANOSTORAGE

The invention relates to traceable metallic products, methods of uses and methods of making same. The metallic products may be made traceable for integrity purposes, identification purposes, counterfeit avoidance and the like. The invention also relates to metallic supports for nanostorage of various compounds and samples. 1. A traceable metallic product , wherein said metallic product comprises a porous surface layer formed by anodization , and wherein said porous surface layer comprises at least one traceable biological compound.2. (canceled)3. The traceable metallic product of claim 1 , wherein said at least one traceable biological compound is selected from the group consisting of nucleic acids claim 1 , peptidic molecules claim 1 , lipids claim 1 , mono and polysaccharides claim 1 , hormones claim 1 , vitamins claim 1 , and derivatives thereof.4. (canceled)5. The traceable metallic product of claim 1 , wherein said at least one traceable biological compound is carried in nanopores of the porous surface layer claim 1 , and wherein said at least one traceable compound is recoverable from said porous surface layer for detection claim 1 , identification and/or utilization purposes.6. (canceled)7. The traceable metallic product of claim 1 , wherein said traceable metallic product consists of a metallic support for nanostorage of compound and samples.8. The traceable metallic product of claim 1 , wherein said porous surface layer is sealed.9. The traceable metallic product of claim 1 , wherein said porous surface layer further comprises an electrodeposit of at least one metal selected from the group consisting of silver claim 1 , gold claim 1 , copper claim 1 , nickel claim 1 , zinc claim 1 , tin claim 1 , cadmium claim 1 , palladium and platinum.10. The traceable metallic product of claim 1 , wherein said traceable metallic product consists of a traceable piece of aluminum comprising a porous surface layer formed by anodization claim 1 , and wherein said porous ...

Conjugates comprising self-immolative groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

VALVE SIGNATURE DIAGNOSIS AND LEAK TEST DEVICE

A valve signature diagnosis and leak testing device includes a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position. A blocker valve is fluidly connected to a control fluid outlet of the spool valve. An electrical module is operatively connected to the pilot valve, a supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or closed position.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody. 1. A ligand-drug conjugate , comprising a ligand; a linker covalently coupled to the ligand; and at least two active agents covalently coupled to the linker , wherein:the linker comprises a peptide sequence of a plurality of amino acids; andat least two of the active agents are covalently coupled to side chains of the amino acids.2. The conjugate of claim 1 , wherein the ligand is an antibody.3. The conjugate of claim 1 , wherein at least two of the active agents are covalently coupled to side chains of lysine claim 1 , 5-hydroxylysine claim 1 , 4-oxalysine claim 1 , 4-thialysine claim 1 , 4-selenalysine claim 1 , 4-thiahomolysine claim 1 , 5 claim 1 ,5-dimethyllysine claim 1 , 5 claim 1 ,5-difluorolysine claim 1 , trans-4-dehydrolysine claim 1 , 2 claim 1 ,6-diamino-4-hexynoic acid claim 1 , cis-4-dehydrolysine claim 1 , 6-N-methyllysine claim 1 , diaminopimelic acid claim 1 , ornithine claim 1 , 3-methylornithine claim 1 , α-methylornithine claim 1 , citrulline claim 1 , and/or homocitrulline.48-. (canceled)9. The conjugate of claim 1 , wherein the plurality of amino acids comprises alanine claim 1 , aspartate claim 1 , asparagine claim 1 , glutamate claim 1 , glutamine claim 1 , glycine claim 1 , histidine claim 1 , lysine claim 1 , ornithine claim 1 , proline ...

Protein-active agent conjugates and method for preparing the same

Conjugates comprising peptide groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g. , wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Antibody-drug conjugates comprising branched linkers and methods related thereto

The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.

Conjugates comprising self-immolative groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

composições e métodos relacionados a conjugados de anticorpo-fármaco anti-cd19

A presente divulgação refere-se a conjugados de anticorpo-fármaco (ADCs), em que um ou mais agentes ativos sãos conjugados a um anticorpo anti-CD19 através de um ligante. O ligante pode compreender uma unidade que covalentemente liga agentes ativos ao anticorpo. A divulgação ainda se refere a anticorpos monoclonais e fragmentos de ligação a antígeno, variantes, versões multiméricas, ou biespecíficos dos mesmos que especificamente ligam CD19, bem como métodos de produzir e usar esses anticorpos anti-CD19 e fragmentos de ligação a antígeno dos mesmos em uma variedade de indicações terapêuticas, diagnósticas e profiláticas.

吡咯并苯二氮卓类衍生物及其配体-接头偶联物

本发明涉及吡咯并苯二氮卓类衍生物化合物、与其配体的偶联物及其用途，在血浆中更稳定，在循环时也稳定，显出优秀的功效(efficacy)，并且，尤其是与配体的偶联物嫁接了药物在癌细胞内轻易释放而使药效最大化的接头技术，偶联物能够在更为稳定地到达靶向细胞来有效发挥药效的同时，能够大幅降低毒性，对于能够使癌症之类的增殖性疾病的靶向化、特异性治疗、药效的极大化及副作用表达的最小化的方面来说，在临床上具有很大的优点。

Compositions and Methods for siRNA Inhibition of Angiogenesis

包含分支接头的抗体-药物缀合物及其相关方法

本发明涉及一种抗体‑药物缀合物(ADC)，其中多个活性剂通过至少一个分支接头与抗体缀合。分支接头可以包含支化单元，并且两个活性剂通过二级接头与支化单元偶联，并且支化单元通过一级接头与抗体偶联。活性剂可以是相同的或不同的。在某些这样的实施方式中，两个或更多个这样的分支接头与抗体缀合，例如2‑4个分支接头，其可以各自与抗体的重链或轻链的不同C端半胱氨酸偶联。分支接头可以包含通过第一分支和第二分支与支化单元偶联的一个活性剂，并且第二分支包含与支化单元偶联的聚乙二醇部分。在某些这样的实施方式中，两个或更多个这样的分支接头与抗体缀合，例如2‑4个分支接头，其可以各自与抗体的重链或轻链的不同C端半胱氨酸偶联。

System for cleaning and sanitizing

The present invention provides a system ( 10 ) for cleaning and sanitizing surfaces that incorporates a high pressure fluid supply ( 52 ) and a low pressure fluid supply ( 42 ), often carrying an ozonated fluid, and alternates directed streams of the two fluids for application to contaminated surfaces through a single applicator ( 70, 100 ).

COMPOSITION

Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain

Disclosed is a cysteine engineered antibody compriDisclosed is a cysteine engineered antibody comprising a free cysteine amino acid having a thiol reasing a free cysteine amino acid having a thiol reactivity value in the range of 0.6 to 1.0; and a sectivity value in the range of 0.6 to 1.0; and a sequence in the heavy chain selected from SEQ ID NOSquence in the heavy chain selected from SEQ ID NOS: 11, 12, 13, and 15: LVTVCSASTKGPS SEQ ID NO:11 : 11, 12, 13, and 15: LVTVCSASTKGPS SEQ ID NO:11 LVTVSCASTKGPS SEQ ID NO:12 LVTVSSCSTKGPS SEQ ID LVTVSCASTKGPS SEQ ID NO:12 LVTVSSCSTKGPS SEQ ID NO:13 HTFPCVLQSSGLYS SEQIDNO:15 where the cysteiNO:13 HTFPCVLQSSGLYS SEQIDNO:15 where the cysteine in SEQ ID NOS: 11, 12, 13, and 15 is the free cne in SEQ ID NOS: 11, 12, 13, and 15 is the free cysteine amino acid. Also disclosed are antibody-drysteine amino acid. Also disclosed are antibody-drug conjugate compounds with the cysteine engineereug conjugate compounds with the cysteine engineered antibody described above and a drug moiety selecd antibody described above and a drug moiety selected from a maytansinoid, an auristatin, a dolastatted from a maytansinoid, an auristatin, a dolastatin, and a calicheamicin. in, and a calicheamicin.

Ligand-drug conjugate including linker having tris structure

The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.

Protein-active agent conjugates and method for preparing the same

The invention provides protein- active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates, as well as methods for making the conjugates and compositions. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Compound containing self-immolative group

本发明提供了一种包含自脱落基团的化合物，本发明的包含自脱落基团的化合物可以包括对靶标具有底物特异性的蛋白(例如，寡肽、多肽、抗体等)和具有特定功能或活性的活性剂(例如，药物、毒素、配体、检测探针等)。

Conjugates comprising peptide groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Antibody-drug conjugates comprising branched linkers and methods related thereto

The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.

Conjugates comprising self-immolative groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Antibody-active agent conjugates and methods of use

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Antibody-active agent conjugates and methods of use

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Protein-active agent conjugates and method for preparing the same

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates, as well as methods for making the conjugates and compositions. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Compounds comprising self-immolative group

Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Solenoid actuated butterfly valve

A butterfly valve (100) and a valve system using the butterfly valve are disclosed. The butterfly valve includes a valve body (102) and a valve disk (112) disposed in the body such that the valve disk may be rotated between at least a first position and a second position using a linear actuator. The actuator may be a linear solenoid coupled to the valve disk spaced a distance from the axis of rotation of the valve disk.

Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.

Energy activated printing process

给出了反应性油墨和在基材上使用反应性且热激活的油墨产生图像的方法。在基材上印刷图像，而不使该油墨中的反应试剂反应。随后，使该反应试剂反应而将图像显著持久且牢固地固定到基材上。还将印刷的升华或类似热激活的染料印刷在该基材上。该升华或类似热激活的染料被激活，并且对施加到基材上的聚合物具有亲合性。

Method and apparatus for making insulating translucent panel assemblies

A method of making an insulating translucent panel assembly (10) such as a window or door lite is provided. In the method, a spacer (16) between two translucent panels (12) of glass or plastic includes a thermo- responsive sealing material (22). When heat and compression are applied to the spacer (16), the thermo-responsive sealing material (22) softens and fully seals the spacer (16) to the two translucent panels (12). A spacer (16) designed to be used in this method is also provided.

Patent DE4028660C2

Liquid flourescent dye concentrate for flow cytometry evaluation of virus-size particles and related products and methods

A kit, and method for flow cytometry include a liquid dye concentrate for fluorescent staining of virus-size particles with a plurality of fluorogenic dyes in a liquid medium. The liquid dye concentrate includes a plurality of fluorogenic dyes and one or both of (i) the liquid medium comprising a liquid mixture including water and liquid phase organic material and (ii) disaccharide dissolved in the liquid medium.

Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Compositions and methods for inhibiting beta-lactamase

Provided herein are substituted dihydroisoxazole derivatives useful as inhibitors of β-lactamases. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.

Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof

Disclosed is a novel oxazolidinone derivative, particularly a novel oxazolidinone compound with a cyclic amidoxime or cyclic amidrazone group. Also disclosed is a pharmaceutical antibiotic composition including a novel oxazolidinone derivative, in vivo hydrolysable ester thereof, in vivo hydrolysable phosphate ester thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as an effective ingredient. Because the novel oxazolidinone derivative, in vivo hydrolysable ester thereof, in vivo hydrolysable phosphate ester thereof, an isomer thereof or a pharmaceutically acceptable salt thereof exhibits a wide antibacterial spectrum against resistant bacteria, a low toxicity, and a strong antibacterial activity against Gram-positive and Gram-negative bacteria, it can be usefully used as an antibiotic.

Method of constructing and executing a process

Disclosed is a method of constructing and executing a process. A conventional process is minutely divided into minimum unit subprocesses, and the minutely divided subprocesses are classified into a decision subprocesses and a routine subprocess by whether they require decision-making. Any subprocess which is executable using the setup condition in a specific decision subprocess is classified into the routine subprocess in such a manner that the classified routine subprocess follows on the specific decision subprocess. One or a series of decision subprocesses are combined with one or a series of routine subprocesses which are executable on the condition of the completion of the decision subprocesses to form one unit process, and a job-support computer program is created to allow the plurality of subprocesses included in the one unit process to be successively executed. A plurality of subprocesses which are executable in accordance with common input data are detected from the minutely divided minimum unit subprocesses, and a job flow is constructed to allow the respective jobs in the plurality of subprocesses to be simultaneously initiated and executed in parallel. The present invention can drastically reduce the lead-time of a process while facilitating execution of the entire process with high efficiency.

Enclosed proximity switch assembly

An enclosed proximity switch assembly includes a top enclosure and a bottom enclosure that are coupled to form an interior volume. A shaft protrusion upwardly extends from a top surface of the top enclosure, and an interior bore portion having an enclosed volume is defined within the shaft protrusion to form a portion of the interior volume. A first end of a vertical shaft is rotatably disposed within the interior bore portion such that the shaft rotates relative to the top and bottom enclosures. A samarium cobalt target magnet is coupled to the shaft, and the target magnet interacts with a samarium cobalt driver magnet within a proximity switch when the target magnet is rotated within a predetermined distance of a top portion of the proximity switch. The interaction causes a switch to move from a first state to a second state, or vice versa.

Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof

Disclosed is a novel oxazolidinone derivative, particularly a novel oxazolidinone compound with a cyclic amidoxime or cyclic amidrazone group. Also disclosed is a pharmaceutical antibiotic composition including a novel oxazolidinone derivative, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as an effective ingredient. Because the novel oxazolidinone derivative, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof exhibits a wide antibacterial spectrum against resistant bacteria, a low toxicity, and a strong antibacterial activity against Gram-positive and Gram-negative bacteria, it can be usefully used as an antibiotic. (see formula I)

Component of printed circuit boards

A component (10) for use in manufacturing articles, such as printed circuit boards, comprising a laminate constructed of a sheet of copper foil (20) that, in a finished circuit board, constitutes a functional element, and a sheet of carbon steel (14) having a layer of an inert metal (16) thereon, the sheet of carbon steel (14) constituting a discardable element. One surface (22) of the copper sheet (20) and the surface (18) of the inert metal layer (16) on the carbon steel sheet (14) are essentially uncontaminated and engageable with each other at interfaces. The copper sheet (20) is attached to the inner metal layer (16) of the carbon steel (14) at their borders and defines substantially uncontaminated central zones inwardly of the edges of the sheets that are unjoined at the interfaces.

Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same

The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism. ording to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.

Data generating device, data generating method and data generating program

Protein-active agent conjugates and method for preparing the same.

La invención proporciona conjugados de agente proteína-activo que tienen un motivo aminoácido que se puede reconocer por una isoprenoide transferasa. La invención también proporciona composiciones que contienen los conjugados así como métodos para elaborar los conjugados y composiciones. La invención proporciona además métodos para utilizar los conjugados para suministrar el agente activo a una célula objetivo, así como métodos para utilizar los conjugados para tratar a un sujeto en necesidad del mismo (por ejemplo, un sujeto en necesidad del agente activo).

Systems and methods for providing, reloading, and redeeming stored value cards used in transit applications

The invention is directed to systems and methods of conducting transactions associated with a transit card. A method of conducting transactions may be conducted between a processor and a transit processor. Steps may include receiving a redemption request and determining if it is a pre-authorization request or a redemption; if the redemption request is a pre-authorization request, determining if the account is authorized for a particular transit type. If the account is authorized, communicating approval to the transit processor. If the account is not authorized communicating denial. If the redemption request is a redemption: determining if account value is sufficient to pay the redemption amount; if not, denying and if so approving the transaction and deducting the amount, and determining if the account value is below a pre-determined threshold for a particular transit types, and if so, updating the status of the account at a data store.

Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

Antibody-drug conjugates comprising branched linkers and methods related thereto

【課題】複数の活性剤が、少なくとも1つの分岐リンカーを介して抗体に複合している抗体-薬物複合体(ADC)を提供する。【解決手段】リガンド、及びリガンドに共有結合で連結する1つ以上の分岐リンカーを含むリガンド-薬物複合体であって、i)各分岐リンカーが、一次リンカー(PL)によりリガンドに共有結合で連結する分岐ユニット(BR)を含み、ii)各分岐リンカーが、第1の分岐(B1)を含み、第1の活性剤が、二次リンカー(SL)及び切断基(CG)により分岐ユニットに共有結合で連結し、iii)各分岐リンカーが、第2の分岐(B2)をさらに含み、a)第2の活性剤が、二次リンカー(SL)及び切断基(CG)により分岐ユニットに共有結合で連結し、又はb)ポリエチレングリコール部分が、分岐ユニットに共有結合で連結し、各切断基が、リガンド-薬物複合体から活性剤を放出するように、加水分解することができる。【選択図】図１

Novel compounds such as autotaxin inhibitors and pharmaceutical compositions that comprise them

La presente invención se refiere a compuestos novedosos como inhibidores de autotoxinas para el tratamiento y profilaxis de afecciones o trastornos causados por la activación de autotaxinas o aumento de la concentración de ácido lisofosfatídico, y también a una composición farmacéutica que los contiene. Los nuevos compuestos de la presente invención son inhibidores de autotoxinas y, al inhibir la producción de ácido lisofosfatídico, son útiles para el tratamiento o la profilaxis de trastornos cardiovasculares, cáncer, trastornos metabólicos, trastornos renales, trastornos hepáticos, trastornos inflamatorios, trastornos del sistema nervioso, trastornos respiratorios. trastorno del sistema, enfermedad fibrótica, trastorno ocular, colestásico y otras formas de prurito crónico, o rechazo agudo o crónico del trasplante de órganos. (Traducción automática con Google Translate, sin valor legal) The present invention relates to novel compounds as autotoxin inhibitors for the treatment and prophylaxis of conditions or disorders caused by activation of autotaxins or increased concentration of lysophosphatidic acid, and also to a pharmaceutical composition containing them. The novel compounds of the present invention are autotoxin inhibitors and, by inhibiting the production of lysophosphatidic acid, are useful for the treatment or prophylaxis of cardiovascular disorders, cancer, metabolic disorders, renal disorders, liver disorders, inflammatory disorders, systemic disorders nervous, respiratory disorders. system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic rejection of organ transplantation. (Automatic translation with Google Translate, without legal value)

Protein-active agent conjugates and method for preparing the same

本发明提供了具有可被类异戊二烯转移酶识别的氨基酸基序的蛋白质-活性剂缀合物。本发明还提供了包含缀合物的组合物，以及用于制备缀合物和组合物的方法。本发明进一步提供了使用缀合物将活性剂递送至靶细胞的方法，以及使用缀合物对需要治疗的个体(例如需要活性剂的个体)进行治疗的方法。

Dual/variable gain oil pump control valve

A solenoid fluid control valve is disclosed for controlling a variable displacement pump. The solenoid fluid control valve comprises a fixed solenoid component (702), a movable armature component (710), a fixed nozzle body (722), a movable spool (720) within the fixed nozzle body, and a valve member (714). The valve member regulates fluid pressure in a first (746, 748) and second feedback chamber. Fluid in the second feedback chamber establishes a second feedback pressure that acts on the movable spool with a motive feedback force in a first axial direction. The movable spool moves in the first axial direction in response to the motive feedback force.

A kind of industrial waste gas dust treatment device

本实用新型公开了一种工业废气粉尘处理装置，包括壳体，所述壳体内壁的顶部对称设置有第一支撑柱，两个第一支撑柱的底部通过第一吸尘管固定连接，所述壳体顶部的中点处固定连接有吸尘风机，所述吸尘风机的底部从上至下依次贯穿壳体和第一吸尘管且延伸至第一吸尘管的内部。本实用新型通过壳体、第一吸尘管、吸尘风机、过滤水箱、第二吸尘管、第三吸尘管、冲刷水箱、第一水管、冲刷喷头、旋转电机、旋转转轴、滚筒、海绵吸附棒、活性炭吸附层、过滤板、出水口、循环水池、循环水泵、第三水管和第四水管相互配合，起到了防逸散的效果，能够有效去除废气中的粉尘，保护了工作人员的身体健康，提高了工作人员的工作积极性。

Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same

Novel oxazolidinone derivative and medical composition containing same

The present invention relates to a novel oxazolidinone derivative indicated as chemical formula 1 on the description, and in particular, to a novel oxazolidinone compound having a cyclic amidoxime or a cyclic amidrazone group. In the chemical formula 1, R and Q are identical to as defined in the detailed explanation. In addition, the present invention relates to an antibiotic medical compound having the novel oxazolidinone derivative of the chemical formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, and a pharmaceutically permitted salt thereof, as active ingredients. The novel oxazolidinone derivative of the present invention, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically permitted salt thereof, have a wide antibacterial spectrum for resistant bacteria, have low toxicity, and show strong antibacterial effect on gram positive and gram negative bacteria, and is thereby useful as an antibiotic.

Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Compositions and methods related to anti-cd19 antibody drug conjugates

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD 19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD 19, as well as methods of making and using these anti-CD 19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Solenoid actuated butterfly valve

A butterfly valve (100) and a valve system using the butterfly valve are disclosed. The butterfly valve includes a valve body (102) and a valve disk (112) disposed in the body such that the valve disk may be rotated between at least a first position and a second position using a linear actuator. The actuator may be a linear solenoid coupled to the valve disk spaced a distance from the axis of rotation of the valve disk.

Trans-septal cardiac occluder device

本发明涉及一种可穿越间隔心脏封堵器装置(1)，包括：·‑支撑结构(2)；其中·‑所述支撑结构(2)包括界定内腔(4)的中心支撑结构部分(3)；·‑所述支撑结构(2)包括第一锚固部分(5)和相对的第二锚固部分(6)；·‑所述支撑结构(2)被配置成在用于通过患者的脉管系统插入的压缩管状配置与扩张或延伸配置之间扩张和收缩，在扩张或延伸配置中所述第一和第二锚固部分(5，6)从所述中心支撑结构部分(3)径向向外延伸以通过以下来压缩其间的间隔(7)：通过存在于所述间隔(7)中的缺损或孔或开口将所述支撑结构(2)布置成跨在所述间隔(7)上；并且其中·‑所述可穿越间隔心脏封堵器装置(1)进一步包括至少一个隔离件(8)；·‑所述隔离件(8)由所述支撑结构(2)支撑并且被布置成当所述隔离件(8)处于其中所述支撑结构(2)被延伸的松弛配置时闭合所述内腔(4)的大部分；·‑所述隔离件(8)被配置成允许插入到由所述间隔(7)界定的第一区室(9或10)中的医疗仪器穿过所述隔离件(8)，以及然后穿过所述内腔(4)进入由所述间隔(7)界定的第二区室(10或9)；其中·‑所述隔离件(8)包括多个长型膜封堵条状物或桥(21)或封堵桥(21)；·‑所述封堵桥(21)的每个包括长型本体(50)，所述长型本体具有相对的长型本体端部或端部(51，52)和相对的纵向边缘或边(22)；·‑在所述隔离件(8)的松弛配置中，所述多个封堵桥(21)中的每个封堵桥(21)被布置成接近于所述多个封堵桥(21)中的至少另一个封堵桥(21)；·‑每个封堵桥(21)的所述纵向边(22)的至少一部分和所述至少另一个封堵桥(21)的所述纵向边(22)的至少一部分界定在所述隔离件(8)上的至少一个狭缝或一个切口(27)；·‑每个封堵桥(21)的两个所述相对的端部(51，52)直接或间接地连接到所述支撑结构(2)上或由所述支撑结构(2)支撑。

Protein-active agent conjugates and method for preparing the same

Automated method for direct sampling of immune cells from whole blood or other biological samples in microwell plates

A method for automatic sampling of immune cells from a biological fluid sample, e.g., whole blood, deposited in a well of a microwell plate. The sample contains red blood cells (RBCs) and magnetic beads which are designed to bind to the RBCs. The microwell plate is placed on a shaker having a magnetic adapter including at least one magnet. The magnet causes the RBCs bound to the magnetic beads to be attracted to and migrate to a wall of the well (e.g., the bottom or side wall) and be held against the wall. The shaker is then operated to shake the microwell plate in a manner and for a time period so as to suspend substantially evenly or homogeneously the immune cells in the biological fluid sample within a region of the well but still retain the holding of the RBCs to the wall of the well such that the immune cells are substantially isolated from the RBCs in the region of the well. During or after shaking, a sample probe is then lowered into the region of the well to withdraw a portion of the sample containing the immune cells.

Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

The present invention relates to compounds represented by the general chemical formula 1: where X is CH; Y is N; R is indanyl; and Q is an optionally substituted five-membered heteroarylene having 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur. Also disclosed are pharmaceutical compositions containing the same. The compounds are useful as autotaxin inhibitors for treatment or prophylaxis of a condition or disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid. The novel autotaxin inhibitors, by inhibiting the production of lysophosphatidic acid, are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Passive reduction or elimination of frost and fog

Lens fogging or frosting on inside surfaces of an instrument lens may be reduced or prevented by sealing the instrument housing. Damage or rupture of the sealed housing due to an increase or decrease in pressure within the housing may be avoided while reducing introduction of moisture into the housing by venting the housing through a tube to a location having a relatively lower humidity.

Method of securing optical fiber components, devices and fibers to the same or to mounting fixtures

A method of bonding glass-based optical elements comprising the steps of positioning a first glass-based optical element relative to a second glass-based optical element, applying a glass-based bonding compound about the first and second optical elements, and applying sufficient localized heat to the glass-based bonding compound to cause the glass-based bonding compound to soften and fuse with the optical elements.

Systems and methods for authorizing use of validly sold merchandise

The invention is generally directed to a method of managing the activation and use of a specific merchandise, facilitated between at least a retailer that sells the specific merchandise, a customer that purchases the specific merchandise, and a central processor that authorizes activation and use of the specific merchandise. The method includes the steps of receiving an indicia that uniquely identifies the specific merchandise, and an activation code associated with the merchandise that will allow the merchandise to properly function, storing the indicia of the specific merchandise and the activation code, receiving a confirmation of a valid purchase transaction of the specific merchandise, the confirmation of valid sale comprising the indicia of the specific merchandise, determining the activation code associated with the specific merchandise, and providing the activation code associated with the specific merchandise to the customer.

Proximity switch

Proximity switches are disclosed that preferably are provided in a hermetically sealed unit that can be used in harsh environments and under significant pressures, such as underwater and in nuclear power facilities, without having any parts that would require replacement or periodic maintenance. The proximity switches are preferably switches actuated by physical movement of a contact in response to changing magnetic forces. The switches are preferably disposed in a body tube optionally including a hermetic seal assembly to seal an open end of the body tube and/or a ferrule that prevents electrical wires attached to the switch inside the body tube from being pulled away from the switch. Further, the switches preferably maintain a contact pressure between electrical contacts sufficient to withstand acceleration seismic testing of 10g with no contact discontinuity.

Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof

Disclosed is a novel oxazolidinone derivative, particularly a novel oxazolidinone compound with a cyclic amidoxime or cyclic amidrazone group. Also disclosed is a pharmaceutical antibiotic composition including a novel oxazolidinone derivative, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof as an effective ingredient. Because the novel oxazolidinone derivative, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof or a pharmaceutically acceptable salt thereof exhibits a wide antibacterial spectrum against resistant bacteria, a low toxicity, and a strong antibacterial activity against Gram-positive and Gram-negative bacteria, it can be usefully used as an antibiotic.

Compositions and methods related to anti-CD19 antibody drug conjugates

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Automatically define system behavior or user experience by recording, sharing, and processing information related to wide-angle images

Novel oxazolidinone derivative and pharmaceutical composition including the same

QUICK DISCONNECT CONNECTOR ASSEMBLY

Un ensamble conector de desconexión rápida incluye una cubierta que tiene un hueco que se extiende hacia arriba pero no pasa a través de un primer extremo de la cubierta. El ensamble conector también incluye un interruptor de proximidad colocado dentro del hueco, y el interruptor de proximidad incluye un cuerpo del interruptor, un primer miembro de contacto y un segundo miembro de contacto. Una parte de cada uno del primer y segundo miembro de contacto se extiende desde el cuerpo del interruptor hasta un segundo extremo de la cubierta. En una primera posición del interruptor, un contacto de un ensamble de conmutación deslizable está en contacto con el primer miembro de contacto, y en una segunda posición del interruptor, el contacto está en contacto con el segundo miembro de contacto. El ensamble conector también incluye un ensamble de conexión externa que incluye una primera clavija que está acoplada eléctricamente al primer miembro de contacto y una segunda clavija que está acoplada eléctricamente al segundo miembro de contacto. A quick disconnect connector assembly includes a cover that has a recess that extends upward but does not pass through a first end of the cover. The connector assembly also includes a proximity switch placed inside the gap, and the proximity switch includes a switch body, a first contact member and a second contact member. A part of each of the first and second contact member extends from the switch body to a second end of the cover. In a first position of the switch, a contact of a sliding switch assembly is in contact with the first contact member, and in a second position of the switch, the contact is in contact with the second contact member. The connector assembly also includes an external connection assembly that includes a first pin that is electrically coupled to the first contact member and a second pin that is electrically coupled to the second contact member.

Die design support method and die design support system

The present invention provides a die design support method and system capable of reducing the time-period required for a die design, allowing an unskilled die engineer to perform a die design without difficulties, and coping with a product design change in a short time-period. A standard die design procedure is stored as “master die data” in advance using a function of a CAD system or the like. When a product design data is entered, the design procedure is automatically executed to the design data in accordance with the stored master die data. Preferably, the entire master die data is divided into a plurality of processes, such as a process of creating a scaling model, and a process of creating a parting model.

Circuit and method for independent control of series connected light emitting diodes

Described herein is a circuit and method for independent control of series connected light emitting diodes (LEDs). The circuit includes a first light emitting diode (LED) connected in series with a second LED. A current source is connected in series with the first LED and the second LED and a shunt circuit is connected in parallel with the first LED and the second LED. The shunt circuit includes a pair of serially connected resistors. The shunt circuit prevents inadvertent excitement of the LEDs due to leakage currents but minimally affect illumination characteristics of the LEDs. A pair of transistors is connected to the first LED and the second LED, respectively, and is biased using a set of bias resistors. A tri-state control signal switches on and off the pair of transistors and enables excitation of the first LED, the second LED or both via the current source.

Electronic-integration compatible photonic integrated circuit and method for fabricating electronic-integration compatible photonic integrated circuit

An electronic-integration compatible photonic integrated circuit (EIC-PIC) for achieving high-performance computing and signal processing is provided. The electronic-integration compatible photonic integrated circuit comprises a plurality of electronic circuit structures and a plurality of photonic circuit structures. The electronic and photonic circuit structures are integrated by a process referred to as monolithic integration. An electronic circuit structure includes one or more electronic devices and a photonic circuit structure includes one or more photonic devices. The integration steps of electronic and photonic devices are further inserted into standard CMOS process. The photonic circuit structures and the electronic circuit structures are integrated to form the electronic-integration compatible photonic integrated circuit device.

AUTOMATIC DEFINITION OF SYSTEM BEHAVIOR OR USER EXPERIENCE BY RECORDING, SHARING AND PROCESSING INFORMATION ASSOCIATED WITH WIDE ANGLE IMAGE

DEFINIÇÃO AUTOMÁTICA DE COMPORTAMENTO DO SISTEMA OU EXPERIÊNCIA DO USUÁRIO POR REGISTRO, COMPARTILHAMENTO E PROCESSAMENTO DE INFORMAÇÃO ASSOCIADA COM IMAGEM DE ÂNGULO AMPLO. Sistemas e métodos de acordo com a invenção permitem registro, compartilhamento e comunicação automáticos de parâmetros diferentes associados com imagens e seu gerador de imagem para definir um comportamento do sistema específico de um dispositivo de exibição, ou de uma unidade de algoritmo. Exemplos de informação incluem parâmetro dos geradores de imagem, parâmetros do ambiente, parâmetros de processamento e intensificação de imagem, coordenadas de uma seção de conteúdo de imagem de cena de ângulo amplo, parâmetros de exibição, experiência do usuário definida, comportamento do sistema definido, ou qualquer informação a ser registrada, compartilhada, e comunicada. Para evitar perda de informação, a informação é codificada diretamente na cena usando um marcador. Desse modo, a informação é robustamente transferida a partir do gerador de imagem para a unidade de exibição. De acordo com a informação, a imagem final pode ser automaticamente corrigida e intensificada antes da exibição, parâmetros associados diferentes podem ser exibidos na imagem final, ou serem usados com outra saída. A experiência final do usuário, ou comportamento do sistema, pode, desse modo, ser definido e ser reproduzido.

Die design support method and die design support system

The present invention provides a die design support method and system capable of reducing the time-period required for a die design, allowing an unskilled die engineer to perform a die design without difficulties, and coping with a product design change in a short time-period. A standard die design procedure is stored as "master die data" in advance using a function of a CAD system or the like. When a product design data (10) is entered, the design procedure is automatically executed to the design data in accordance with the stored master die data. Preferably, the entire master die data is divided into a plurality of processes, such as a process of creating a scaling model (12), and a process of creating a parting model (14).

A kind of flexible package labeling thermal transfer heating device

一种软包装贴签用热转印加热装置，包括定位块，所述定位块的上端设有第一电机，所述定位块内穿接有丝杆，所述丝杆的上端连接所述第一电机，所述丝杆的下端连接有加热环，所述加热环的轴线和所述丝杆垂直设置，所述加热环的下端设有缺口，所述缺口不大于所述加热环本体的二分之一；所述加热环内对应设有与所述加热环大小相适配的加热辊，所述加热辊与所述加热环之间留有间隙；所述加热辊的中央活动穿接设有固定管；所述加热环上均匀、固定穿接有若干电热棒，所述若干电热棒均连接有电源。本装置能提高防伪标签热转印效率，保证产品质量。

Automated definition of system behavior or user experience by recording, sharing, and processing information associated with wide-angle image

Systems and methods in accordance with the invention allow automatic recording, sharing, and communicating of different parameters associated with images and their imager to define a specific system behavior of a display device or an algorithm unit. Examples of information include imager parameters, environment parameters, image processing and enhancement parameters, display parameters, defined user experience, defined system behavior or the likes. To avoid loss of information, the information is encoded directly in the picture using a marker. This way, the information is robustly transferred from the imager to the display unit. According to the information, the final image can be automatically corrected and enhanced before display, different associated parameters can be displayed on final image or be used with another output. The end user experience or system behavior can thus be defined and be reproduced.

Software development support program, recording medium having the program stored thereon and software development support system

Respective items of a software component, a development task and a required specification, which are enumerated as the requirement for performing the development of software products belonging to a certain category are first registered in recording means. In the registration of the development-task items, when a specific development-task item can be initiated only after the completion of one or more other development-task items at the time of the registration, the specific development-task item is registered together with ordinal information specifying the one or more other development-task items. Then, the operator is allowed to set up the correlations between any two of the software component, the development task and the required specification which have been registered by the item registration function, with respect to each of the items thereof, and information about the correlations is registered in the recording means.

Extruded plastic window trim strip

Systems and methods for providing, reloading, and redeeming stored value cards used in transit applications.

La invención se relaciona con sistemas y métodos para llevar a cabo transacciones asociadas con una tarjeta de tránsito. Un método para llevar a cabo transacciones puede ser realizado entre un procesador y un procesador de tránsito. Las etapas pueden incluir recibir una solicitud de finiquito y determinar si existe una solicitud de preautorización o un finiquito; si la solicitud de finiquito es una solicitud de preautorización, determinar si la cuenta está autorizada para un tipo de tránsito particular. Si la cuenta está autorizada, comunicar aprobación al procesador de tránsito. Si la cuenta no está autorizada, comunicar prohibición. Si la solicitud de finiquito es un finiquito: determinar si el valor de la cuenta es suficiente para pagar la cantidad de finiquito; de no ser así, prohibir y si es así, aprobar la transacción y detectar la cantidad y determinar si el valor de cuenta está por debajo de un umbral predeterminado para un tipo de tránsito particular y, en caso de ser así, actualizar el estado de la cuenta en el almacenamiento de datos.